Vanda Pharmaceuticals to Announce Second Quarter 2016 Financial Results on July 27, 2016
Conference Call and Webcast to Follow
Get Alerts VNDA Hot Sheet
Join SI Premium – FREE
WASHINGTON, July 12, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2016 on Wednesday, July 27, 2016, after the market closes.
Vanda will host a conference call at 4:30 PM ET on Wednesday, July 27, 2016, during which management will discuss the second quarter 2016 financial results and other corporate activities. To participate in the conference call, please dial 1-888-771-4371 (domestic) or 1-847-585-4405 (international) and use passcode 42972056.
The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Wednesday, July 27, 2016, beginning at 7:00 PM ET and will be accessible until Wednesday, August 3, 2016, at 11:59 PM ET. The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The passcode number is 42972056.
ABOUT VANDA PHARMACEUTICALS INC.:Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.
Investor Contact:Jim KellySenior Vice President & Chief Financial OfficerVanda Pharmaceuticals Inc.(202) 734-3428[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-second-quarter-2016-financial-results-on-july-27-2016-300297591.html
SOURCE Vanda Pharmaceuticals Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Primis Financial (FRST) Misses Q1 EPS by 8c
- Vanda Pharmaceuticals (VNDA) Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!